DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial.

Abstract

We carried out a double-blind study of a vasopressin-related peptide, DGAVP citrate (Org 5667), in 115 patients with mild dementia, probable Alzheimer's type (DAT). Neither clinical rating scales nor psychometric tests revealed any improvement over 84 days with once-daily intranasal treatment with 2 different doses of DGAVP. We conclude that vasopressin-like peptides are not satisfactory therapeutic agents in DAT.

• Authors: E C Wolters, P Riekkinen, A Lowenthal, J J Van der Plaats, J M Zwart, C Sennef
• Journal: Neurology (Neurology) Vol. 40 Issue 7 Pg. 1099-101 (Jul 1990) ISSN: 0028-3878 [Print] United States
• PMID: 2192301 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Arginine Vasopressin
• argipressin, des-GlyNH2(9)-

Topics

• Aged
• Aged, 80 and over
• Alzheimer Disease (drug therapy, physiopathology)
• Arginine Vasopressin (analogs & derivatives, therapeutic use)
• Chi-Square Distribution
• Double-Blind Method
• Humans
• Middle Aged
• Multicenter Studies as Topic
• Psychiatric Status Rating Scales
• Randomized Controlled Trials as Topic